Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Government Opposes Proposed Illumina/Grail Merger

Executive Summary

Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.

You may also be interested in...



PacBio Agrees To Pay $800M For Omniome To Add Complementary Short-Read Sequencing Platform

Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.

Merger Scrutiny A Bigger Risk To Pharma Than Drug Price Reform, Orzag Predicts

US antitrust regulators appear poised to take a broader view of disease areas when reviewing mergers, Lazard Freres financial advisory CEO Peter Orszag cautioned.

Merger Scrutiny A Bigger Risk To Pharma Than Drug Price Reform, USAIC Panelist Predicts

US antitrust regulators appear poised to take a broader view of disease areas when reviewing mergers, Lazard Freres financial advisory CEO Peter Orszag cautioned.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT143724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel